Table 4.
Outcomes and Adverse Events
| Adverse Events | TACE+IT Group (N=24) | IT Group (N=24) | ||
|---|---|---|---|---|
| Toxicity Grade | I/II | III/IV | I/II | III/IV |
| Liver dysfunction (transaminitis) | 11 (45.8) | 1 (4.2) | 2 (8.3) | 0 |
| Proteinuria | 6 (25.0) | 0 (0) | 6 (25.0) | 0 (0) |
| Fatigue | 6 (25.0) | 0 (0) | 4 (16.7) | 0 (0) |
| Gastrointestinal reaction | 9 (37.5) | 1 (4.2) | 2 (8.3) | 1 (4.2) |
| Anorexia | 3 (12.5) | 0 (0) | 2 (8.3) | 0 (0) |
| Hypertension | 6 (25.0) | 0 (0) | 7 (29.2) | 0 (0) |
| Hand-foot syndrome | 9 (37.5) | 1 (4.2) | 8 (33.3) | 2 (8.3) |
| Skin rash | 2 (8.3) | 0 (0) | 1 (4.2) | 0 (0) |
| Hyperthyroidism | 4 (16.7) | 0 (0) | 4 (16.7) | 0 (0) |
| Hypothyroidism | 5 (20.8) | 0 (0) | 4 (16.7) | 0 (0) |
| RCCEP | 3 (12.5) | 0 (0) | 3 (12.5) | 0 (0) |
| Liver abscess | 1 (4.2) | 0 (0) | 0 (0) | 0 (0) |
| Fever | 13 (54.2) | 1 (4.2) | 1 (2.5) | 0 (0) |
| Nausea and vomiting | 5 (20.8) | 0 (0) | 0 (0) | 0 (0) |
| Pain | 10 (41.7) | 2 (8.3) | 0 (0) | 0 (0) |
| Immune-related hypophysitis | 0 (0) | 1 (4.2) | 0 (0) | 0 (0) |
Abbreviations: TACE, transcatheter arterial chemoembolization; IT, immune checkpoint inhibitors plus tyrosine kinase inhibitors; RCCEP, reactive cutaneous capillary endothelial proliferation.